Conditions: Colorectal Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 62
Healthy volunteers: no

Brief summary:
This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer. Eligible participants will receive Xeloda 825mg/m\^2 orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment. The anticipated time on study treatment is \< 3 months, and the target sample size is \< 100 individuals.

Detailed description:

Arms:
arm 1: Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.

Interventions: intervention 1: Standard radiotherapy intervention 2: Capecitabine [Xeloda]
Intervention descriptions: intervention 1: Administered as prescribed according to normal clinical practice. intervention 2: 825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.

Protocol document: